US Patent

US10709694 — Methods of treating hepatic encephalopathy

Method of Use · Assigned to Salix Pharmaceuticals Inc · Expires 2029-07-24 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating hepatic encephalopathy using gastrointestinal specific antibiotics, such as rifaximin.

USPTO Abstract

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

Drugs covered by this patent

Xifaxan (rifaximin) · Bausch Health

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2579`	—	Xifaxan

Patent Metadata

Patent number: US10709694
Jurisdiction: US
Classification: Method of Use
Expires: 2029-07-24
Drug substance claim: No
Drug product claim: No
Assignee: Salix Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.